Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region
4.9.2023 11:00:00 EEST | Business Wire | Press release
Eigenmann & Veronelli S.p.A., a leading distributor in the specialty chemicals and food ingredients industry, today announced that it has acquired 100% of IMEA Technologies FZC, a regional distribution company of specialty chemicals with a focus on the industrial market, based in the United Arab Emirates.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230904875181/en/
Eigenmann & Veronelli announces the acquisition of IMEA Technologies to accelerate growth in the MEA region. (Photo: Business Wire)
The acquisition represents an excellent fit with E&V’s existing operations and a strategic commercial expansion in the Middle East and Africa region, in addition to the Far East and Indian markets, reinforcing its international footprint to consolidate its compelling portfolio and execute its growth strategy.
IMEA Technologies was founded in 2011, in Sharjah (U.A.E.), and offers a wide range of products, mainly industrial, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetic & cleaning applications.
Headquartered in Sharjah, with offices & warehouses in U.A.E., the Company ensures the full coverage of the MEA region in addition to the Far East and Indian markets. In 2022, IMEA Technologies generated revenues of approximately AED 68.5M (ca. EUR 17.7 million).
IMEA Technologies, as part of the E&V Group, will be led by its present management line-up and staff retaining its well-established name.
Gabriele Bonomi, Chief Executive Officer of the E&V Group, comments:
“In line with our strategic vision to be an established international solutions provider, we are delighted to welcome IMEA Technologies to the E&V Group. This acquisition strengthens our international footprint and allows us to offer a truly compelling value proposition to both principals and customers.”
Ayoob Chekkintakath, Executive Director of IMEA Technologies, adds:
“Becoming part of E&V, a key international market player, marks a milestone in our company’s evolution. We share a similar vision and culture, and I am confident that IMEA Technologies will continue to thrive as part of the E&V Group, continuing its long-term relationships with key suppliers and customers.”
ABOUT EIGENMANN & VERONELLI S.p.A.
Eigenmann & Veronelli is an international solutions provider in the specialty chemicals and food ingredients industry with a direct presence in 4 countries and a commercial reach in more than 30. Headquartered in Rho, Milan, Italy, E&V is synonymous with effectiveness and efficiency, combining local market knowledge with international chemical innovations. In 2022 the E&V Group generated a consolidated turnover of EUR 417 M with 340 employees.
To find out more about E&V, please visit: www.eigver.com
ABOUT IMEA TECHNOLOGIES FZC
IMEA Technologies is a regional distributor of specialty chemicals, specialized in industrial market, such as emulsion polymers for industries, paints, plastic, inks, water treatment, sealants & adhesives, oil & gas, and construction, as well as cosmetics & cleaning applications. Headquartered in Saif Zone, Sharjah (U.A.E.), with offices and warehouses in U.A.E. IMEA Tech. posted a consolidated turnover of EUR 17.7 M in 2022.
To find out more, please visit: www.imeatech.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230904875181/en/
Contact information
Press Contact
Federica Urso
Group Corporate Communication Manager, E&V S.p.A
mediarelations@eigver.it - +39 338.7295116
Commercial Contact
Ayoob Chekkintakath
Executive Director, IMEA TECHNOLOGIES FZC
info@imeatech.com - +971 6 5574800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom